Abatacept, a CTLA4–Fc fusion protein that modulates T-cell activation, has been developed for the treatment of rheumatoid arthritis. Tay et al. evaluated the effect of abatacept on vaccination ...
The initiation of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), particularly rituximab and abatacept, is associated with an increased risk for incident cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback